Peptide approval status in the UK
Where each of the 68 compounds stands in the UK, from the MHRA’s product register, checked October 7, 2026.
This summarizes approval status. It isn’t legal advice: rules on importing, prescribing and possessing medicines differ and change. “No marketing authorization” means no approved product was found, nothing more.
- SemaglutideApproved drug
- Prescription-only medicines licensed by the MHRA: Ozempic and Rybelsus for type 2 diabetes; Wegovy injection for weight management in adults and teens 12+, and Wegovy tablets for adults (2026).
- TirzepatideApproved drug
- Prescription-only medicine licensed by the MHRA as Mounjaro: type 2 diabetes from age 10, and weight management in adults (added November 2023).
- RetatrutideHuman studies
- No marketing authorization (MHRA).
- CagrilintideHuman studies
- No marketing authorization; the MHRA lists no cagrilintide product.
- AOD9604Human studies
- No marketing authorization (MHRA).
- 5-Amino-1MQPreclinical
- No marketing authorization (MHRA).
- SLU-PP-332Preclinical
- No marketing authorization (MHRA).
- L-CarnitineApproved drug
- Prescription-only medicine (POM): levocarnitine oral solutions are licensed by the MHRA for primary and secondary carnitine deficiency in children under 12.
- HGH Fragment 176-191Preclinical
- No marketing authorization (MHRA).
- LiraglutideApproved drug
- Prescription-only medicines licensed by the MHRA: Victoza and generic pens for type 2 diabetes from age 10; Saxenda and generic pens for weight management in adults and teens 12+.
- ExenatideApproved drug
- Prescription only. Byetta and Bydureon licenses remain on the MHRA register, but Bydureon BCise pens were discontinued in 2025 and supplies have run out.
- SurvodutideHuman studies
- No marketing authorization (MHRA).
- MazdutideApproved drug
- No marketing authorization (MHRA).
- OrforglipronApproved drug
- Licensed by the MHRA as Foundayo tablets (August 10, 2026) for adults, both for weight management and for type 2 diabetes.
- TesofensineHuman studies
- No marketing authorization (MHRA).
- NAD+Human studies
- No marketing authorization (MHRA).
- MOTS-cPreclinical
- No marketing authorization (MHRA).
- SS-31Approved drug
- No marketing authorization (MHRA).
- GlutathioneApproved drug
- No marketing authorization (MHRA); no glutathione medicine is listed in the UK medicines compendium.
- EpithalonPreclinical
- No marketing authorization; FDA’s 2026 review found no approved UK product.
- HumaninPreclinical
- No marketing authorization (MHRA).
- FOXO4-DRIPreclinical
- No marketing authorization (MHRA).
- BPC-157Preclinical
- No marketing authorization (MHRA).
- TB-500Preclinical
- No marketing authorization; FDA’s 2026 review found no approved TB-500 product in the UK.
- KPVPreclinical
- No marketing authorization; FDA found no approved KPV product in any country.
- ARA-290Human studies
- No marketing authorization.
- CartalaxPreclinical
- No marketing authorization (MHRA).
- MGFPreclinical
- No marketing authorization; no MGF product appears in the MHRA’s product database.
- PEG-MGFPreclinical
- No marketing authorization; no PEG-MGF product appears in the MHRA’s product database.
- Thymosin Beta-4Human studies
- No marketing authorization.
- LarazotideHuman studies
- No marketing authorization (MHRA).
- CJC-1295 (no DAC)Preclinical
- No marketing authorization (MHRA); FDA’s 2024 review found no approved CJC-1295 product in the UK.
- CJC-1295 with DACHuman studies
- No marketing authorization (MHRA); FDA’s 2024 review found no approved CJC-1295 product in the UK.
- IpamorelinHuman studies
- No marketing authorization (MHRA); no ipamorelin product is listed in the UK’s electronic Medicines Compendium.
- SermorelinHuman studies
- No marketing authorization (MHRA); no sermorelin product is listed in the UK’s electronic Medicines Compendium.
- TesamorelinApproved drug
- No marketing authorization (MHRA); no tesamorelin product is listed in the UK’s electronic Medicines Compendium.
- IGF-1 LR3Preclinical
- No marketing authorization (MHRA); not listed in the UK’s electronic Medicines Compendium, where Increlex is the IGF-1 medicine.
- GHRP-2Approved drug
- No marketing authorization (MHRA).
- GHRP-6Human studies
- No marketing authorization (MHRA).
- HexarelinHuman studies
- No marketing authorization (MHRA).
- MK-677Human studies
- No marketing authorization (MHRA).
- IGF-1 DESPreclinical
- No marketing authorization (MHRA); not listed in the UK’s electronic Medicines Compendium, where Increlex is the IGF-1 medicine.
- Follistatin-344Preclinical
- No marketing authorization (MHRA); no follistatin product is listed in the UK’s electronic Medicines Compendium.
- GHK-CuHuman studies
- No marketing authorization (MHRA). Cosmetics containing it fall under UK cosmetics law rather than medicines regulation.
- AHK-CuPreclinical
- No marketing authorization (MHRA). Cosmetics containing it fall under UK cosmetics law rather than medicines regulation.
- SNAP-8Human studies
- No marketing authorization (MHRA). Cosmetics containing it fall under UK cosmetics law rather than medicines regulation.
- Melanotan 1Approved drug
- Licensed by the MHRA as Scenesse 16 mg implant for adults with EPP (GB license since January 1, 2021). No tanning product is licensed.
- Melanotan 2Human studies
- No marketing authorization; no melanotan II product appears in the MHRA’s product database.
- ArgirelineHuman studies
- No marketing authorization (MHRA). Cosmetics containing it fall under UK cosmetics law rather than medicines regulation.
- MatrixylHuman studies
- No marketing authorization (MHRA). Cosmetics containing it fall under UK cosmetics law rather than medicines regulation.
- hCGApproved drug
- Prescription-only medicines (MHRA): recombinant Ovitrelle and urine-derived Zivafert, licensed to trigger ovulation, including in IVF. Another urinary product, Ovulgone, also holds a UK license.
- Kisspeptin-10Human studies
- No marketing authorization; the MHRA product database lists no kisspeptin product.
- PT-141Approved drug
- No marketing authorization; the MHRA product database lists no bremelanotide product.
- OxytocinApproved drug
- Prescription-only medicines (MHRA): Syntocinon and generic oxytocin for infusion or injection, and Syntometrine (with ergometrine). No nasal product is licensed.
- GonadorelinApproved drug
- Prescription-only: a 100 microgram gonadorelin injection (HRF) is licensed by the MHRA for a single pituitary function test.
- TriptorelinApproved drug
- Prescription-only (MHRA): Decapeptyl SR 3, 11.25 and 22.5 mg for prostate cancer, endometriosis, fibroids, early puberty and early breast cancer; Salvacyl for severe sexual deviations.
- SelankApproved drug
- No marketing authorization; no Selank product in the MHRA’s products database.
- SemaxApproved drug
- No marketing authorization; no Semax product in the MHRA’s products database.
- AdamaxPreclinical
- No marketing authorization; no product in the MHRA’s products database.
- DSIPApproved drug
- No marketing authorization; no product in the MHRA’s products database.
- CerebrolysinApproved drug
- No marketing authorization; no Cerebrolysin product in the MHRA’s products database.
- PinealonPreclinical
- No marketing authorization (MHRA).
- DihexaHuman studies
- No marketing authorization; no dihexa product in the MHRA’s products database.
- PE-22-28Preclinical
- No marketing authorization; no PE-22-28 product in the MHRA’s products database.
- Thymosin Alpha-1Approved drug
- No marketing authorization; no thymalfasin product in the MHRA’s products database.
- ThymalinApproved drug
- No marketing authorization (MHRA).
- VIPApproved drug
- Invicorp (aviptadil with phentolamine) is a prescription medicine licensed by the MHRA for erectile dysfunction; current license since 2022. No authorization for VIP alone.
- LL-37Human studies
- No marketing authorization; no LL-37 product appears in the MHRA’s product database.